SRR5088856
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- DNA_REPAIR+0.400
- MYC_TARGETS_V1+0.400
- OXIDATIVE_PHOSPHORYLATION+0.300
- KRAS_SIGNALING_DN+0.100
- SPERMATOGENESIS+0.100
- E2F_TARGETS+0.000
- GLYCOLYSIS+0.000
- P53_PATHWAY+0.000
- ESTROGEN_RESPONSE_EARLY-0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- ANGIOGENESIS-0.500
- COMPLEMENT-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- MITOTIC_SPINDLE-0.500
- TGF_BETA_SIGNALING-0.500
- ALLOGRAFT_REJECTION-0.400
- ANDROGEN_RESPONSE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088853 | — | — | 0.930 |
| 2 | R16 | — | — | 0.907 |
| 3 | SRR1364893 | GTEX | — | 0.899 |
| 4 | cf2834ac-00ed-4372-be25-042f38241196 | — | — | 0.897 |
| 5 | TCGA-DK-AA75-01A-11R-A39I-07 | — | — | 0.893 |
| 6 | TCGA-OL-A5RZ-01A-11R-A28M-07 | — | C | 0.887 |
| 7 | SRR2016956 | — | — | 0.882 |
| 8 | SRR1340420 | GTEX | — | 0.879 |
| 9 | 264656b8-d45c-4f5c-a431-366c566296fe | — | — | 0.875 |
| 10 | TCGA-P3-A6T6-01A-11R-A34R-07 | — | — | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |